Written by Our Editorial Team
Last updated: 1/23/23
What is PT-141
PT-141, also known as bremelanotide, is a peptide hormone that has been developed to treat sexual dysfunction in both men and women. It was developed from the peptide hormone Melanotan-II. In initial testing, Melanotan-II induced darkening of skin pigment but additionally caused sexual arousal and spontaneous erections as unexpected side effects in nine of the ten original male volunteer test subjects. Further animal testing showed it to induce sexual mating behaviors, and subsequently, researchers began testing it in humans.
As a result, PT-141 is now used as an FDA-approved medication for treating sexual dysfunction in men (erectile dysfunction or impotence) and women (sexual arousal disorder). One study found that men who were unresponsive to/unhappy with Viagra preferred PT-141. And another study in women found it caused a 50% increase in sexually satisfying experiences.
PT-141 currently has no contraindications, and it’s effective even in some men who don’t typically respond to Viagra or Cialis.
How Does it work?
PT-141 works by activating the melanocortin receptors in the brain, which regulate sexual arousal and desire. That is to say, PT-141 targets the brain regions responsible for regulating our sexual desire rather than simply increasing blood flow in the penis as a PDE5 inhibitor (i.e., Cialis, Viagra) would.
In other words, it has more of a mental effect than a physical one.
Even though PT-141 can also act on the MC1R receptor, we don’t see the tanning/darkening of the skin observed with Melanotan 2.
- PT-141 is FDA-approved for hypoactive sexual desire disorder for both men and women.
- In women, it causes a 50% increase in sexually satisfying experiences.
- PT-141 increases sexual desire (through your brain) rather than arousal (what happens physically, i.e., after taking Viagra).
- It can treat both organic and psychological male sexual dysfunction.
- Compared to other sexual enhancement drugs, PT-141 kicks in almost instantly, whereas other drugs can take hours.
Users have reported
- Lower refractory period
- Increased erectile strength
- Enhanced libido
- Increased sexual desire
- Enhanced orgasms
- Improved stamina
- Heightened penile sensitivity
Recent clinical trials have shown that PT-141 effectively treats female sexual arousal disorder (FSAD) and male erectile disorder (ED).
In one study, more than two-thirds of women reported increased desire and arousal, and more than half reported improved lubrication and orgasm.
Similarly, more than two-thirds of men reported an increase in erectile function, and over half reported an increase in sexual satisfaction.
A 2016 study in women taking PT-141 for 12 weeks found an increase in the number of sexually satisfying events and orgasm score, with no adverse events.
In addition to effectively treating sexual dysfunction, PT-141 is also being studied for its potential to treat other conditions such as depression, anxiety, and PTSD. Preliminary research suggests that PT-141 may help regulate the brain’s response to stress and improve mood.
PT-141 has also been studied for its potential to treat obesity. In animal studies, PT-141 has been found to reduce appetite and body weight.
The libido-boosting effects of PT-141 can last multiple days. Because of the long half-life, it allows spontaneity in the bedroom to remain. It is often recommended that men or women administer the medication twice weekly. The peak effect takes hold 2 hours after administering. The most effective administration method is a subcutaneous injection beneath the skin.
Using it more than eight times a month is not recommended by the FDA.
Warning: Contact your nearest emergency room if your erection lasts more than 2 hours.
In the U.S., ED (erectile dysfunction) affects nearly 20 million men, and FSD (female sexual dysfunction) affects around 30 million women. PT-141 could be a significant game-changer. Users of PT-141 report experiencing stronger sexual desire, bodily engagement, and performance.
Disclaimer: This blog post/article is for informational purposes only and does not constitute medical advice. This is not a substitute for professional medical advice and should not be relied upon. If you are considering a treatment, always consult your primary care physician to discuss the risks and benefits.
Hadley, Mac E., and Robert T. Dorr. “Melanocortin Peptide Therapeutics: Historical Milestones, Clinical Studies and Commercialization.” Peptides, vol. 27, no. 4, 2006, pp. 921–930., https://doi.org/10.1016/j.peptides.2005.01.029.
Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004 Apr;16(2):135-42. doi: 10.1038/sj.ijir.3901200. PMID: 14999221.
Shadiack AM, Sharma SD, Earle DC, Spana C, Hallam TJ. Melanocortins in the treatment of male and female sexual dysfunction. Curr Top Med Chem. 2007;7(11):1137-44. doi: 10.2174/156802607780906681. PMID: 17584134.